These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38882672)

  • 1. PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma.
    Liu X; Liu M; Wu H; Tang W; Yang W; Chan TTH; Zhang L; Chen S; Xiong Z; Liang J; Wai-Yiu Si-Tou W; Shu T; Li J; Cao J; Zhong C; Sun H; Kwong TT; Leung HHW; Wong J; Bo-San Lai P; To KF; Xiang T; Jao-Yiu Sung J; Chan SL; Zhou J; Sze-Lok Cheng A
    JHEP Rep; 2024 Jul; 6(7):101087. PubMed ID: 38882672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
    Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
    JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
    Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
    Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.
    Xu Y; Zhao W; Xu J; Li J; Hong Z; Yin Z; Wang X
    Oncotarget; 2016 Feb; 7(8):8866-78. PubMed ID: 26758420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
    Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
    Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
    Lu LC; Chang CJ; Hsu CH
    J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis.
    Liu T; Gonzalez De Los Santos F; Rinke AE; Fang C; Flaherty KR; Phan SH
    Front Immunol; 2022; 13():901349. PubMed ID: 36045668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.
    Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T
    Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Stellate Cells Enhance Liver Cancer Progression by Inducing Myeloid-Derived Suppressor Cells through Interleukin-6 Signaling.
    Hsieh CC; Hung CH; Chiang M; Tsai YC; He JT
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified method for differentiation of myeloid-derived suppressor cells
    Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
    Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
    Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
    J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma.
    Xu Y; Fang F; Jiao H; Zheng X; Huang L; Yi X; Zhao W
    Cancer Immunol Immunother; 2019 Dec; 68(12):1959-1969. PubMed ID: 31641797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma.
    Yokota S; Yonezawa T; Momoi Y; Maeda S
    Vet Immunol Immunopathol; 2024 Mar; 269():110716. PubMed ID: 38308864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid-derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications.
    Yue Y; Ren Z; Wang Y; Liu Y; Yang X; Wang T; Bai Y; Zhou H; Chen Q; Li S; Zhang Y
    Immun Inflamm Dis; 2024 Sep; 12(9):e70007. PubMed ID: 39222024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
    Zeng X; Liao G; Li S; Liu H; Zhao X; Li S; Lei K; Zhu S; Chen Z; Zhao Y; Ren X; Su T; Cheng AS; Peng S; Lin S; Wang J; Chen S; Kuang M
    Hepatology; 2023 Apr; 77(4):1122-1138. PubMed ID: 35598182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mTOR Deficiency in Monocytic Myeloid-Derived Suppressor Cells Protects Mouse Cardiac Allografts by Inducing Allograft Tolerance.
    Li J; Chen J; Zhang M; Zhang C; Wu R; Yang T; Qiu Y; Liu J; Zhu T; Zhang Y; Rong R
    Front Immunol; 2021; 12():661338. PubMed ID: 33897705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.